


# U.S. Breast Cancer Statistics by State

## BREAST CANCER DIAGNOSES BY STATE

This map outlines the prevalence of diagnoses by volume, and highlights the trends for the top 3 states based on patient volume data derived from LexisNexis® MarketView™ medical claims data.\*



### NEW YORK

#1 state for breast cancer diagnoses

163,436 diagnoses (9.29% of all U.S.)

12.82% of breast cancer patients ages 19-34 are seen in NY


### TEXAS

#3 state for breast cancer diagnoses  
117,740 diagnoses (6.7% of all U.S.)

### FLORIDA

#2 state for breast cancer diagnoses  
143,111 diagnoses (8.14% of all U.S.)

### CASES BY STATE



## TOP STATES FOR BREAST CANCER DIAGNOSIS PROCEDURES

### States ranked by overall volume of **breast MRI**

NY	9,787
FL	5,762
MI	5,155
OH	4,832
CA	4,716
GA	2,571
TX	2,098
MN	2,028
MD	2,008
NJ	1,945

### States ranked by overall volume of **mammogram**

NY	1,312,268
MI	827,186
OH	819,787
TX	796,783
CA	741,663
FL	654,569
PA	644,116
IL	545,775
GA	464,279
NJ	404,817

To learn more about breast cancer trends or other claims-based insights by payer, drug and geography to drive strategy decisions, call 866.396.7703, or visit [risk.lexisnexis.com/products/marketview](http://risk.lexisnexis.com/products/marketview)



Health Care

\*Data used in this analysis represents the most recent 12 months of LexisNexis available data ending September 2019.

MarketView provided by LexisNexis is not provided by “consumer reporting agencies” as that term is defined in the Fair Credit Reporting Act (15 U.S.C. § 1681, et seq.) (“FCRA”) and does not constitute a “consumer report” as that term is defined in the FCRA. MarketView may not be used in whole or in part as a factor in determining eligibility for credit, insurance, or employment or for any other eligibility purpose that would qualify it as a consumer report under the FCRA. Due to the nature and origin of public record information, the public records and commercially available data sources used in reports may contain errors. Source data is sometimes reported or entered inaccurately, processed poorly or incorrectly, and is generally not free from defect. This product or service aggregates and reports data, as provided by the public records and commercially available data sources, and is not the source of the data, nor is it a comprehensive compilation of the data. Before relying on any data, it should be independently verified. LexisNexis and the Knowledge Burst logo are registered trademarks of RELX Inc. Other products and services may be trademarks or registered trademarks of their respective companies. Copyright © 2019 LexisNexis. All rights reserved.